Trientine Tetrahydrochloride (Cuprior®/Cuvrior®)
Wilson Disease
ApprovedActive
Key Facts
About Orphalan
Orphalan SA is a global, commercial-stage orphan drug company focused on rare diseases, with a primary anchor in Wilson disease. The company has successfully developed and gained marketing authorization for its lead product, trientine tetrahydrochloride (Cuprior®/Cuvrior®), which is now available in over 30 countries. Through recent strategic acquisitions, such as Orphelia Pharma, and expansion into key markets like China and the US, Orphalan is building a broader rare disease portfolio, particularly in pediatric neurology and oncology. The company employs over 100 people and maintains a dedicated international team across more than 20 countries.
View full company profileTherapeutic Areas
Other Wilson Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Copper Chelator | DepYmed | Pre-clinical |
| UX701 | Ultragenyx Pharmaceutical | Phase 1/2 |
| Undisclosed (Liver) | Prime Medicine | Preclinical |
| ALXN1840 | Monopar Therapeutics | Phase 3 |